First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-... by Özgüroğlu, Mustafa, Prof, Kilickap, Saadettin, Prof, Sezer, Ahmet, Prof, Gümüş, Mahmut, Prof, Bondarenko, Igor, Prof, Gogishvili, Miranda, MD, Nechaeva, Marina, MD, Schenker, Michael, Prof, Cicin, Irfan, Prof, Ho, Gwo Fuang, Prof, Kulyaba, Yaroslav, MD, Zyuhal, Kasimova, MD, Scheusan, Roxana-Ioana, MD, Garassino, Marina Chiara, Prof, He, Xuanyao, PhD, Kaul, Manika, MD, Okoye, Emmanuel, MPH, Li, Yuntong, PhD, Li, Siyu, PhD, Pouliot, Jean-Francois, PhD, Seebach, Frank, MD, Lowy, Israel, MD, Gullo, Giuseppe, MD, Rietschel, Petra, MD

Get full text